See more : SUZHOU KEMATEK INC (301611.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Odonate Therapeutics, Inc. (ODTC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Odonate Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Exela Technologies, Inc. (XELAP) Income Statement Analysis – Financial Results
- SAMSRITA LABS LIMITED (SAMSRITA.BO) Income Statement Analysis – Financial Results
- Folangsi Co Ltd (2499.HK) Income Statement Analysis – Financial Results
- Seres Therapeutics, Inc. (MCRB) Income Statement Analysis – Financial Results
- Singer India Limited (SINGER.BO) Income Statement Analysis – Financial Results
Odonate Therapeutics, Inc. (ODTC)
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 21.00K | 342.00K | 1.05M | 870.00K | 381.00K | 350.00K | 20.00K | 0.00 | 0.00 |
| Gross Profit | -21.00K | -342.00K | -1.05M | -870.00K | -381.00K | -350.00K | -20.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 36.48M | 117.04M | 104.03M | 79.95M | 27.90M | 2.62M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 796.00K | 3.58M | 9.29M | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 796.00K | 3.58M | 45.77M | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | 158.00K |
| Cost & Expenses | 817.00K | 3.92M | 46.82M | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | 158.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 21.00K | 342.00K | 1.05M | 870.00K | 381.00K | 350.00K | 20.00K | 22.82K | 0.00 |
| EBITDA | 9.47M | -3.58M | -45.77M | -125.48M | -111.44M | -88.61M | -32.72M | -3.09M | -158.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -817.00K | -3.92M | -46.82M | -127.43M | -114.93M | -90.76M | -32.74M | -3.09M | -158.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.26M | 13.56M | -21.49M | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 9.44M | 9.64M | -68.32M | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.12M | -33.30M | 814.44K | 238.70K | -3.11M | 1.80M | 0.00 | -22.82K | 0.00 |
| Net Income | 7.33M | 42.94M | -68.32M | -126.35M | -108.72M | -88.96M | -32.74M | -3.09M | -158.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 2.56 | 14.77K | -900.72 | -1.92K | -1.80K | -1.82K | -1.16K | -267.70 | -85.62 |
| EPS Diluted | 2.55 | 14.74K | -900.72 | -1.92K | -1.80K | -1.82K | -1.16K | -267.70 | -85.62 |
| Weighted Avg Shares Out | 2.86M | 2.91K | 75.85K | 65.73K | 60.54K | 48.91K | 28.34K | 11.52K | 1.85K |
| Weighted Avg Shares Out (Dil) | 2.87M | 2.91K | 75.85K | 65.73K | 60.54K | 48.91K | 28.34K | 11.52K | 1.85K |
Source: https://incomestatements.info
Category: Stock Reports